Aimmune Therapeutics Inc AIMT:NASDAQ

Last Price$25.15NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/18/19

Today's Change0(0.00%)
Bid (Size)$25.02 (1)
Ask (Size)$25.50 (3)
Day Low / HighN/A - N/A
Volume443.0 K
 

View Biotechnology IndustryPeer Comparison as of 10/18/2019

 

Aimmune Therapeutics Inc ( NASDAQ )

Price: $25.15
Change: -0.14 (0.55%)
Volume: 443.0 K
4:00PM ET 10/18/2019
 
 

Alder Biopharmaceuticals Inc ( NASDAQ )

Price: $18.92
Change: +0.02 (0.11%)
Volume: 7.4 M
4:00PM ET 10/18/2019
 
 

Insmed Inc ( NASDAQ )

Price: $17.42
Change: 0.00 (0.00%)
Volume: 704.6 K
4:00PM ET 10/18/2019
 
 

Heron Therapeutics Inc ( NASDAQ )

Price: $18.45
Change: -0.16 (0.83%)
Volume: 1.1 M
4:00PM ET 10/18/2019
 
 

Momenta Pharmaceuticals Inc ( NASDAQ )

Price: $14.40
Change: +0.25 (1.77%)
Volume: 559.8 K
3:59PM ET 10/18/2019
 

Read more news Recent News

Aimmune Therapeutics' Peanut Allergy Treatment Talked up at Piper Jaffray, Raymond James
9:00AM ET 10/03/2019 MT Newswires

Shares of Aimmune Therapeutics (AIMT) jumped more than 11% intraday after Piper Jaffray analyst Christopher Raymond forecast a "massive upside" for the...

--Analyst Actions: Cantor Fitzgerald Raises Price Target For Aimmune Therapeutics to $55 From $45, Maintains Overweight Rating
11:56AM ET 9/16/2019 MT Newswires

Price: 23.42, Change: -1.25, Percent Change: -5.07 ...

--Analyst Actions: Stifel Nicolaus Raises Aimmune Therapeutics Price Target to $30 From $24, Maintains Hold Rating
11:55AM ET 9/16/2019 MT Newswires

Price: 23.41, Change: -1.26, Percent Change: -5.11 ...

Sector Update: Health Care Giants Mixed Pre-Bell Monday
9:18AM ET 9/16/2019 MT Newswires

Top Health Care Stocks: JNJ: -0.21% PFE: -0.41% ABT: Flat MRK: +0.06% AMGN: Flat Health care giants were mixed in Monday's pre-market trading. Stocks...

Company Profile

Business DescriptionAimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. View company web site for more details
Address8000 Marina Boulevard
Brisbane, California 94005-1884
Phone+1.650.614.5220
Number of Employees215
Recent SEC Filing09/20/20194
President, Chief Executive Officer & DirectorJayson Donald Alexander Dallas
Chief Financial OfficerEric H. Bjerkholt
Chief Medical OfficerDaniel C. Adelman
Senior VP-Corporate Development & StrategyMary M. Rozenman

Company Highlights

Price Open$25.21
Previous Close$25.29
52 Week Range$16.95 - 36.12
Market Capitalization$1.6 B
Shares Outstanding62.7 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/14/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.72
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-89.68%

Analyst Ratings as of 07/11/2019

Buy
7
Overweight
1
Hold
2
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset